Abstract
RIB and PAL are CDK4/6 inhibitors with efficacy and tolerability in pts with HR+/HER2- ABC when administered in combination with endocrine therapy (ET). RNA-based intrinsic subtyping has strong prognostic and predictive value in advanced HR+/HER2- tumors treated with ET. Non-Luminal subtypes, such as HER2-E and basal-like, are relatively endocrine-resistant and have poorer prognosis than luminal. tumors can switch subtypes over time to a more aggressive and less endocrine-responsive biology, which may also be reversed by effective treatment.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
